Hepatitis C Virus (HCV)

CAS No.	Product Name	Inquiry
1334513-10-8	Sofosbuvir impurity J Sofosbuvir impurity J is a diastereoisomer and impurity of Sofosbuvir, an inhibitor of HCV RNA replication with strong anti-hepatitis C virus activity.
1337482-17-3	Sofosbuvir 3',5'-Bis-(S)-phosphate Sofosbuvir 3',5'-Bis-(S)-phosphate, an impurity of PSI-7977, which is a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.
1346601-82-8	Deferiprone-[d3] Deferiprone-[d3] is a labelled product of Deferiprone, which is an iron chelator.
1350462-55-3	MK-5172 hydrate In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose.
1355050-21-3	GS-443902 trisodium GS-443902 trisodium is a potent inhibitor of viral RNA-dependent RNA-polymerases (RdRp), with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively.
1355149-45-9	GS-443902 GS-443902 is a potent inhibitor of viral RNA-dependent RNA-polymerases (RdRp), with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively.
1365970-03-1	glecaprevir Glecaprevir is a suppressive agent of hepatitis C virus (HCV). Glecaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 4.09 μM.
1394157-34-6	Sofosbuvir impurity N Sofosbuvir impurity N is a diastereoisomer and impurity of Sofosbuvir, an inhibitor of HCV RNA replication with strong anti-hepatitis C virus activity.
1401839-25-5	HCV-IN-3 HCV-IN-3 is an inhibitor of hepatitis C virus (HCV) NS3/4a protein, with an IC50 of 20 μM and a Kd of 29 μM.
141117-12-6	Celgosivir hydrochloride Celgosivir hydrochloride is the hydrochloride salt of Celgosivir which is anα-glucosidase inhibitor and inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in vitro assay.
1416334-69-4	GSK-A1 GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research.
1423007-82-2	GSK8175 GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons.
1425038-27-2	MK-5172 sodium salt In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose.
1428729-63-8	RIG-1 modulator 1 RIG-1 modulator 1 is an inhibitor of HBV, HCV and HIV.
143205-42-9	NIM811 NIM811 is a dual inhibitor of mitochondrial permeability transition and cyclophilin. It exhibits potent in vitro inhibitory activity against hepatitis C virus (HCV).
1449756-86-8	HCV-IN-7 HCV-IN-7, a potent and orally active pan-genotypic HCV NS5A inhibitor (IC50 of 3-47 pM) with antiviral activity, demonstrates superior pan-genotypic profile and good pharmacokinetic characteristics, as well as favorable liver uptake.
1449756-87-9	HCV-IN-7 dihydrochloride HCV-IN-7 hydrochloride, a potent and orally active pan-genotypic HCV NS5A inhibitor (IC50 of 3-47 pM) with antiviral activity, demonstrates superior pan-genotypic profile and good pharmacokinetic characteristics, as well as favorable liver uptake.
1456607-71-8	Paritaprevir-dihydrate Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor).
1496551-77-9	Uprifosbuvir Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus.
1496552-16-9	Sofosbuvir impurity A Sofosbuvir impurity A is a diastereoisomer and impurity of Sofosbuvir, an inhibitor of HCV RNA replication with strong anti-hepatitis C virus activity.

※ Please kindly note that our services are for research use only.